



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AJ2-30

Item No. 40667

CAS Registry No.: 2700322-79-6
Formal Name: 9-ethyl-N-(1-methyl-1H-benzimidazol-2-yl)-9H-carbazole-3-methanamin
MF: C₂₃H₂₂N₄
FW: 354.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AJ2-30 is supplied as a solid. A stock solution may be made by dissolving the AJ2-30 in the solvent of choice, which should be purged with an inert gas. AJ2-30 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

AJ2-30 is an inhibitor of the endolysosome transporter solute carrier family 15 member A4 (SLC15A4).¹ It is selective for SLC15A4 over SLC15A3 at 5 μM. AJ2-30 reduces increases in IFN-α levels induced by the toll-like receptor 9 (TLR9) agonist CPG-2216 in primary human plasmacytoid dendritic cells (IC₅₀ = 1.8 μM). It also inhibits NOD2 signaling mediated by the NOD2 ligand muramyl dipeptide (MDP; Item No. 30866) in a reporter assay using A549 cells expressing membrane-localized SLC15A4 (IC₅₀ = 2.6 μM). AJ2-30 reduces increases in IFN-α and IL-6 induced by the TLR9 agonist CPG-2006 or the TLR7 agonist R-837 (imiquimod; Item No. 14956) in peripheral blood mononuclear cells (PBMCs) isolated from patients with systemic lupus erythematosus (SLE). It reduces IFN-α, IFN-β, and IFN-γ production induced by a CPG-2216-DOTAP complex in mice when administered at a dose of 50 mg/kg.

Reference

1. Chiu, T.Y., Lazar, D.C., Wang, W.W., *et al.* Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity. *Nat. Chem. Biol.* Online ahead of print, (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/25/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM